RCOR News and Press, Renovacor Inc Com From 05/12/22

Renovacor press release (NYSE:RCOR): Q1 GAAP EPS of $0.36. Cash and cash equivalents as of March 31, 2022, totaled $70.1 million The company believes will be sufficient to fund its operating expenses and capital expenditures requirements into the second half of 2023. For further details see...

REN-001 advancing toward IND submission in the second half of 2022 with the initiation of a Phase I/II clinical trial in BAG3-DCM expected thereafter Strengthened executive team with appointment of Fred Driscoll as CFO Renovacor, Inc. (NYSE: RCOR), a biotechnology co...

Biotechnology company Renovacor (NYSE:RCOR) has appointed Fred Driscoll as Chief Financial Officer (CFO), replacing interim CFO Wendy DiCicco. Mr. Driscoll holds over 25 years of executive experience in the biotech industry. Most recently, he served as the CFO of Flexion Therapeutics. For f...

Mr. Driscoll has over 25 years of biotech executive experience and most recently served as the CFO of Flexion Therapeutics through its sale to Pacira BioSciences for up to $1 billion Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative preci...

Renovacor press release (NYSE:RCOR): Q4 GAAP EPS of -$0.03. Cash position as of December 31, 2021, totaled $78.8 million For further details see: Renovacor GAAP EPS of -$0.03

Debuted as a public company and raised gross proceeds of $95.1 million from the business combination with Chardan Healthcare Acquisition 2 Corp and a concurrent PIPE financing Strengthened company leadership with key appointments including Marc Semigran, M.D., as CMO, Matthew ...

Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that Magdalene Cook, M.D., Chief Exec...

Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced partnerships with the Dilated Cardiom...

Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and related diseases, today announced that Magdalene Cook, M.D., President and Chief Execut...

Renovacor (NYSE:RCOR): Q3 GAAP EPS of -$0.83. Press Release Cash position as of September 30, 2021, totaled $85.3M which, based on current projections, Renovacor believes will be sufficient to fund its operating expenses and capital expenditures requirements into 2023. For further details s...